recent articles

Aiforia has entered into an exclusive licensing agreement with the Mayo Clinic in the United States to globally commercialize an AI model that improves prediction of colorectal cancer recurrence. Aiforia Technologies Plc - January 2, 2024 at...

Article in Nature Communications demonstrates that with 96% sensitivity, AI diagnostic MSIntuit™ CRC can  rule  out  almost  half  of  the  MSS population of colorectal cancer patients unlikely to respond to checkpoint...

DoMore Diagnostics and Proscia: Collaboration holds the promise to reduce overtreatment with integrated AI-powered pathology workflows OSLO and PHILADELPHIA – August 30, 2023 – DoMore Diagnostics, a leader in deep learning precision...

Lunit: Collaborative study with NCCHE shows that AI analysis of HER2 expression and the tumor microenvironment is linked to treatment response of Pertuzumab+Trastuzumab in colorectal cancer [SEOUL, South Korea, August 1, 2023] Lunit...

Owkin: World's first AI diagnostic for MSI prescreening from routine H&E slides for colorectal cancer aims to help pathologists and oncologists facilitate better access to approved immunotherapy treatments for their patients. PARIS, June...

Read how Orion™ was used to identify improved prognostic signatures for colorectal cancer patients in this publication from Harvard Medical School. "High-plex immunofluorescence imaging and traditional histology of the same tissue section...

OR

platinum partners

gold partners

Silver Partners

Media Partners